| Literature DB >> 24250280 |
Luca Grieco1, Laurence Calzone, Isabelle Bernard-Pierrot, François Radvanyi, Brigitte Kahn-Perlès, Denis Thieffry.
Abstract
The Mitogen-Activated Protein Kinase (MAPK) network consists of tightly interconnected signalling pathways involved in diverse cellular processes, such as cell cycle, survival, apoptosis and differentiation. Although several studies reported the involvement of these signalling cascades in cancer deregulations, the precise mechanisms underlying their influence on the balance between cell proliferation and cell death (cell fate decision) in pathological circumstances remain elusive. Based on an extensive analysis of published data, we have built a comprehensive and generic reaction map for the MAPK signalling network, using CellDesigner software. In order to explore the MAPK responses to different stimuli and better understand their contributions to cell fate decision, we have considered the most crucial components and interactions and encoded them into a logical model, using the software GINsim. Our logical model analysis particularly focuses on urinary bladder cancer, where MAPK network deregulations have often been associated with specific phenotypes. To cope with the combinatorial explosion of the number of states, we have applied novel algorithms for model reduction and for the compression of state transition graphs, both implemented into the software GINsim. The results of systematic simulations for different signal combinations and network perturbations were found globally coherent with published data. In silico experiments further enabled us to delineate the roles of specific components, cross-talks and regulatory feedbacks in cell fate decision. Finally, tentative proliferative or anti-proliferative mechanisms can be connected with established bladder cancer deregulations, namely Epidermal Growth Factor Receptor (EGFR) over-expression and Fibroblast Growth Factor Receptor 3 (FGFR3) activating mutations.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24250280 PMCID: PMC3821540 DOI: 10.1371/journal.pcbi.1003286
Source DB: PubMed Journal: PLoS Comput Biol ISSN: 1553-734X Impact factor: 4.475
Figure 1Molecular map for ERK regulation and sub-cellular localisation.
After RAS activation, ERK cascade can be recruited and activated on plasma membrane with the help of KRS1 scaffold protein (upper part of the figure); activated ERK is then released (in complex with MEK and KSR1) into the cytoplasm, where it can activate some of its cytoplasmic targets (e.g. PLA2G4A protein). Alternatively, activated receptor complex can translocate to late endosomes (left part of the figure), where ERK cascade can be triggered with the help of MP1 scaffold protein; in this case, activated ERK monomers are released into the cytoplasm, from where they can translocate into the nucleus and exert other effects (e.g. induction of DUSP1 phosphatase). This map is a small fraction of the detailed MAPK network built with the software CellDesigner (www.celldesigner.org) and provided in png and cell formats (supplementary Dataset S1 and S2).
Figure 2Regulatory graph of the MAPK logical model.
Each node denotes a model component. Model inputs, phenotypes and MAPK proteins (ERK, p38, JNK) are denoted in pink, blue and orange, respectively. Green arrows and red T-arrows denote positive and negative regulations, respectively. A comprehensive documentation is provided in the Table S4, which includes a summary of all modelling assumptions, references (PubMed links) and the specification of the logical rule associated with each component. The source file is further provided as supplementary Dataset S4, which can be opened, edited, analysed and simulated with the softare GINsim (www://www.ginsim.org/beta).
Figure 3Regulatory graph of a reduced version of the MAPK model.
The regulatory graph corresponds to the “red1” reduced model version (cf. supplementary Table S3, column 1). To obtain this version, the preservation of pink and blue nodes was imposed, along with that of {EGFR, FGFR3, p53, p14, PI3K, AKT, PTEN, ERK}, in order to investigate the effects of perturbations affecting these components. The remaining nodes {FRS2, MSK} were maintained by the reduction algorithm because of the occurrence of auto-regulatory loops during the reduction process. Green arrows and red T-arrows denote positive and negative regulations, respectively, whereas blue arrows denote dual interactions.
Figure 4Coherence of the logical model with well established bladder cancer deregulations.
a) Simplified representation of the model dynamics following EGFR over-expression (EGFR = 1 throughout the simulation and all inputs set to 0 throughout the simulation). If p53 is activated first (right branch), an apoptotic attractor is reached, characterised by inactivation of ERK and AKT. If ERK and PI3K are activated first (left branch), then p53 is inactivated and AKT is activated, leading to a proliferative attractor. b) Simplified representation of the model dynamics following FGFR3 activating mutation (FGFR3 = 1 and all inputs set to 0 throughout the simulation). When p53 is activated first (right branch), an apoptotic attractor is reached, characterised by inactivation of ERK and AKT. If ERK is activated first (left and central branches), then p53 is inactivated. When PI3K is also activated (central), a proliferative attractor is reached, characterised by activated AKT. In contrast, when PI3K is not activated (left), the cell fails to make a clear decision at the level of the MAPK network. c) Attractors reached by the model in presence of receptor alterations, coupled with additional common deregulations observed in bladder cancer. Coloured circles denote the phenotypes characterising the attractors reached in each situation (we used the same colour code as in panels a and b, while empty spaces denote the loss of the corresponding branch in the state transition graph). Identifiers in rectangles (e.g.. r3, r4, etc.) point to simulation results reported in more details in Dataset S3 and Text S2.
Coherence of model simulations with published experimental evidence.
| Reduction | Simulation | Biological data | Model behaviour |
| red2 | r17, r18 | * RAF or RAS over-expressions can lead to constitutive activation of ERK. | In absence of inputs, constitutive activity of any one among RAF or RAS can lead to permanent ERK activation, associated with proliferation. |
| red2 | r19 | * HSP90-inhibitor disrupts RAF, AKT and EGFR, leading to successful cancer treatment | Concomitant RAF, AKT, EGFR deletions abrogate the proliferative stable states observed in the unperturbed model, both in the case of EGFR over-expression (obvious – simulation not performed) and in the case of FGFR3 activating mutation. |
| red2 | r20, r21, r22, r23 | * Patients with p53-altered/p21-negative tumors demonstrated a higher rate of recurrence and worse survival compared with those with p53-altered/p21-positive tumors | Following either EGFR over-expression or FGFR3 activating mutation, concomitant p21 and p53 loss-of-functions correspond to a phenotype characterised by apoptosis escape (Apoptosis = Growth_Arrest = 0), with the possibility to attain proliferation. Association of p53 loss-of-function and p21 gain-of-function leads to growth arrest attractors, all characterised by no proliferation. |
| red3 | r25 | p38 and JNK play important roles in stress responses, such as cell cycle arrest and apoptosis | In presence of either DNA_damage or TGFBR_stimulus, growth arrest/apoptosis stable states are all lost in the p38/JNK-deleted model. |
| red3 | r26 | p38 and JNK, especially in the absence of mitogenic stimuli, have been shown to induce apoptotic cell death | When p38/JNK are constitutively active, apoptotic attractors (Growth_Arrest = Apoptosis = 1, Proliferation = 0) are obtained in the absence of other stimuli. |
| red3 | r27 | p38 plays its tumour suppressive role by promoting apoptosis and inhibiting cell cycle progression | Under JNK constitutive activation, p38 loss-of-function determines loss of apoptotic attractors obtained in r26. |
| red3 | r28 | JNK may contribute to the apoptotic elimination of transformed cells by promoting apoptosis | Under p38 constitutive activation and JNK loss-of-function, all apoptotic attractors obtained in r26 become growth arrest attractors (Growth_Arrest = 1, Apoptosis = 0, Proliferation = 0), thus determining loss of apoptotic attractors obtained in r26. |
| red3 | r29 | Epigenetic gene silencing of GADD45 family members has been frequently observed in several types of human cancers | In presence of DNA_damage (main GADD45 activator), Growth_Arrest and Apoptosis components permanently oscillate when GADD45 is silenced, suggesting less propensity to cell death. Apoptotic stable states are still reached in presence of TGFBR_stimulus |
| red3 | r30 | ERK increases transcription of the cyclin genes and facilitates the formation of active Cyc/CDK complexes, leading to cell proliferation | ERK gain-of-function always leads to proliferative attractors (Proliferation = 1, Growth_Arrest = Apoptosis = 0), in the absence of other stimuli. |
| red3 | r31 | ERK disrupts the anti-proliferative effects of TGFβ | Whereas TGFBR_stimulus leads to an apoptotic stable state (r24), coupling of TGFBR_stimulus with ERK gain-of-function only leads to permanent growth arrest (Growth_Arrest = 1, Apoptosis = 0). |
| red3 | r32 | JNK might reduce RAS-dependent tumour formation by inhibiting proliferation and promoting apoptosis | In absence of other stimuli, JNK constitutive activation completely abrogates RAS-dependent proliferation following RAS over-expression (r18). Instead, apoptotic attractors are always reached. |
Asterisks denote facts explicitly related to bladder cancer, whereas unmarked entries correspond to generic or loosely specified mechanisms. Full simulation results can be found in Dataset S3, with the help of the identifiers provided in the first two columns.
Figure 5FGFR3 activating mutation and role of SPRY.
Simulations were performed under FGFR3 gain-of-function (FGFR3 = 1 and all inputs set to 0, throughout the simulations). Simplified model dynamics are shown as in Figure 4a–b. Results are shown for the wild type model (red1 model reduction), as well as for perturbed model versions obtained by disrupting the inhibition of interest.
Figure 6Analysis of MAPK cross-talks by disruptions of specific interactions.
a) Effects of the disruptions of the inhibitions of MEK by AP1 and the phosphatase PPP2CA. b) Effects of the disruption of the inhibition of p38 or of JNK by the phosphatase DUSP1. These simulations were performed after removing the corresponding interactions and blocking the level of the perturbed receptor to level 1 (with all inputs set to 0, throughout the simulation).